News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
253,600 Results
Type
Article (19719)
Company Profile (175)
Press Release (233702)
Multimedia
Podcasts (50)
Webinars (7)
Section
Business (66818)
Career Advice (212)
Deals (9721)
Drug Delivery (66)
Drug Development (35018)
Employer Resources (34)
FDA (7381)
Job Trends (6604)
News (119763)
Policy (11881)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (2)
Academia (1649)
Academic (1)
Accelerated approval (19)
Adcomms (13)
Allergies (89)
Alliances (19550)
ALS (85)
Alzheimer's disease (785)
Antibody-drug conjugate (ADC) (146)
Approvals (7669)
Artificial intelligence (340)
Autoimmune disease (93)
Automation (20)
Bankruptcy (63)
Best Places to Work (6278)
BIOSECURE Act (7)
Biosimilars (135)
Biotechnology (123)
Bladder cancer (99)
Brain cancer (28)
Breast cancer (350)
Cancer (2617)
Cardiovascular disease (265)
Career advice (197)
Career pathing (7)
CAR-T (165)
CDC (16)
Celiac Disease (1)
Cell therapy (446)
Cervical cancer (14)
Clinical research (31179)
Collaboration (1042)
Company closure (1)
Compensation (413)
Complete response letters (22)
COVID-19 (1174)
CRISPR (73)
C-suite (490)
Cystic fibrosis (95)
Data (3761)
Decentralized trials (1)
Denatured (23)
Depression (69)
Diabetes (293)
Diagnostics (2713)
Digital health (28)
Diversity (8)
Diversity, equity & inclusion (13)
Drug discovery (165)
Drug pricing (120)
Drug shortages (19)
Duchenne muscular dystrophy (142)
Earnings (21696)
Editorial (25)
Employer branding (2)
Employer resources (35)
Events (38261)
Executive appointments (533)
FDA (9202)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (7)
Frontotemporal dementia (13)
Funding (759)
Gene editing (146)
Generative AI (30)
Gene therapy (389)
GLP-1 (565)
Government (1755)
Grass and pollen (2)
Guidances (177)
Healthcare (8212)
HIV (41)
Huntington's disease (28)
IgA nephropathy (55)
Immunology and inflammation (105)
Immuno-oncology (33)
Indications (71)
Infectious disease (1313)
Inflammatory bowel disease (128)
Inflation Reduction Act (7)
Influenza (61)
Intellectual property (98)
Interviews (15)
IPO (4629)
IRA (28)
Job creations (761)
Job search strategy (179)
JPM (34)
Kidney cancer (11)
Labor market (18)
Layoffs (148)
Leadership (8)
Legal (1902)
Liver cancer (42)
Longevity (8)
Lung cancer (368)
Lymphoma (242)
Machine learning (26)
Management (11)
Manufacturing (421)
MASH (96)
Medical device (3810)
Medtech (3829)
Mergers & acquisitions (5551)
Metabolic disorders (741)
Multiple sclerosis (81)
NASH (12)
Neurodegenerative disease (160)
Neuropsychiatric disorders (40)
Neuroscience (1434)
NextGen: Class of 2026 (2427)
Non-profit (1829)
Now hiring (16)
Obesity (349)
Opinion (106)
Ovarian cancer (85)
Pain (125)
Pancreatic cancer (115)
Parkinson's disease (134)
Partnered (19)
Patents (183)
Patient recruitment (261)
Peanut (37)
People (24847)
Pharmaceutical (35)
Pharmacy benefit managers (16)
Phase 1 (8766)
Phase 2 (12709)
Phase 3 (12011)
Pipeline (2828)
Policy (152)
Postmarket research (1452)
Preclinical (3490)
Press Release (22)
Prostate cancer (130)
Psychedelics (16)
Radiopharmaceuticals (167)
Rare diseases (519)
Real estate (1675)
Recruiting (12)
Regulatory (10739)
Reports (19)
Research institute (1453)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (11)
RSV (33)
Schizophrenia (81)
Series A (144)
Series B (113)
Sickle cell disease (77)
Special edition (8)
Spinal muscular atrophy (93)
Sponsored (22)
Startups (1540)
Stomach cancer (7)
Supply chain (50)
Tariffs (52)
The Weekly (26)
Vaccines (422)
Venture capital (47)
Weight loss (225)
Women's health (47)
Worklife (1)
Date
Today (16)
Last 7 days (225)
Last 30 days (978)
Last 365 days (14816)
2026 (1740)
2025 (15098)
2024 (16954)
2023 (18235)
2022 (22292)
2021 (23181)
2020 (21120)
2019 (18521)
2018 (14007)
2017 (12919)
2016 (12035)
2015 (13127)
2014 (9202)
2013 (7622)
2012 (7795)
2011 (7795)
2010 (6272)
Location
Africa (259)
Alabama (39)
Alaska (2)
Arizona (72)
Arkansas (4)
Asia (17100)
Australia (2363)
California (5346)
Canada (1265)
China (600)
Colorado (169)
Connecticut (300)
Delaware (237)
Europe (37965)
Florida (764)
Georgia (196)
Hawaii (1)
Idaho (18)
Illinois (417)
India (37)
Indiana (335)
Iowa (9)
Japan (326)
Kansas (57)
Kentucky (9)
Louisiana (12)
Maine (33)
Maryland (540)
Massachusetts (4405)
Michigan (85)
Minnesota (164)
Mississippi (1)
Missouri (66)
Montana (13)
Nebraska (6)
Nevada (42)
New Hampshire (18)
New Jersey (1789)
New Mexico (19)
New York (1566)
North Carolina (683)
North Dakota (9)
Northern California (2752)
Ohio (139)
Oklahoma (11)
Oregon (30)
Pennsylvania (1013)
Puerto Rico (4)
Rhode Island (23)
South America (323)
South Carolina (10)
Southern California (1965)
Tennessee (56)
Texas (715)
United States (19531)
Utah (181)
Vermont (1)
Virginia (139)
Washington D.C. (45)
Washington State (443)
West Virginia (1)
Wisconsin (57)
Wyoming (1)
253,600 Results for "revolution medicines".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Merck Backs Off Revolution After Failing To Agree on Price: WSJ
Merck had previously offered anywhere from $28 billion to $32 billion to swallow Revolution Medicines.
January 26, 2026
·
1 min read
·
Tristan Manalac
Mergers & acquisitions
Revolution Knows Its Worth as Merck Backs Off—For Now
Investors are apparently taking bets on when Revolution will be acquired. A handful of pharmas could be interested as Merck backs off.
January 26, 2026
·
4 min read
·
Annalee Armstrong
Mergers & acquisitions
Revolution Soars Amid Swirling Buyout Rumors With Merck, AbbVie
Rumors of a Revolution buyout come as the industry gears up for one of its biggest trade conferences, where observers expect many such deals to be announced.
January 9, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Revolution Medicines to Participate in Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 5, 2026
·
1 min read
Press Releases
Revolution Medicines Announces FDA Breakthrough Therapy Designation for Zoldonrasib
January 8, 2026
·
6 min read
Press Releases
Revolution Medicines to Present at 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
·
1 min read
Press Releases
Revolution Medicines to Participate in November 2025 Investor Conferences
November 4, 2025
·
1 min read
Press Releases
Revolution Medicines Doses First Patient in Clinical Trial Evaluating RMC-5127, a RAS(ON) G12V-Selective Inhibitor
January 29, 2026
·
4 min read
Press Releases
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
November 5, 2025
·
12 min read
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field’s therapeutic horizons.
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
1 of 25,360
Next
